Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06287918
Title	A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	3H (Suzhou) Pharmaceuticals Co., Ltd.
Indications	Advanced Solid Tumor
Therapies	3HP-2827
Age Groups:	senior \| adult
Covered Countries	USA